Ultragenyx Pharmaceutical (RARE) Accumulated Expenses (2013 - 2026)

Ultragenyx Pharmaceutical (RARE) has 14 years of Accumulated Expenses data on file, last reported at $57.0 million in Q1 2026.

• Accumulated Expenses for Q1 2026 came in at $57.0 million, down 67.05% year-over-year; the trailing twelve-month figure through Mar 2026 was $57.0 million (down 67.05% YoY), and the FY2025 annual result was $265.0 million, up 181.91% from the prior year.
• Accumulated Expenses retreated to $57.0 million in Q1 2026 per RARE's latest filing, from $265.0 million in the prior quarter.
• Over five years, Accumulated Expenses peaked at $265.0 million in Q4 2025 and troughed at $41.6 million in Q1 2022.
• A 5-year average of $119.2 million and a median of $82.9 million in 2023 frame the typical range for Accumulated Expenses.
• The sharpest annual moves came in 2022 and 2026: Accumulated Expenses soared 310.05% in 2022, then plunged 67.05% in 2026.
• A 5-year view of Accumulated Expenses shows it stood at $204.7 million in 2022, then sank by 59.48% to $82.9 million in 2023, then advanced by 13.34% to $94.0 million in 2024, then surged by 181.91% to $265.0 million in 2025, then tumbled by 78.49% to $57.0 million in 2026.
• Business Quant data shows RARE's Accumulated Expenses at $57.0 million in Q1 2026, $265.0 million in Q4 2025, and $220.5 million in Q3 2025.